Incidence and Survival Among Young Women With Stage I-III Breast Cancer: SEER 2000-2015.

dc.contributor.author

Thomas, Alexandra

dc.contributor.author

Rhoads, Anthony

dc.contributor.author

Pinkerton, Elizabeth

dc.contributor.author

Schroeder, Mary C

dc.contributor.author

Conway, Kristin M

dc.contributor.author

Hundley, William G

dc.contributor.author

McNally, Lacey R

dc.contributor.author

Oleson, Jacob

dc.contributor.author

Lynch, Charles F

dc.contributor.author

Romitti, Paul A

dc.date.accessioned

2024-02-01T14:27:44Z

dc.date.available

2024-02-01T14:27:44Z

dc.date.issued

2019-09

dc.description.abstract

Background

Although recent findings suggest that de novo stage IV breast cancer is increasing in premenopausal women in the United States, contemporary incidence and survival data are lacking for stage I-III cancer.

Methods

Women aged 20-29 (n = 3826), 30-39 (n = 34 585), and 40-49 (n = 126 552) years who were diagnosed with stage I-III breast cancer from 2000 to 2015 were identified from the Surveillance, Epidemiology, and End Results 18 registries database. Age-adjusted, average annual percentage changes in incidence and 5- and 10-year Kaplan-Meier survival curves were estimated by race and ethnicity, stage, and hormone receptor (HR) status and grade (low to well and moderately differentiated; high to poorly and undifferentiated) for each age decade.

Results

The average annual percentage change in incidence was positive for each age decade and was highest among women aged 20-29 years. Increased incidence was driven largely by HR+ cancer, particularly HR+ low-grade cancer in women aged 20-29 and 40-49 years. By 2015, incidence of HR+ low- and high-grade cancer each independently exceeded incidence of HR- cancer in each age decade. Survival for HR+ low- and high-grade cancer decreased with decreasing age; survival for HR- cancer was similar across age decades. Among all women aged 20-29 years, 10-year survival for HR+ high-grade cancer was lower than that for HR+ low-grade or HR- cancer. Among women aged 20-29 years with stage I cancer, 10-year survival was lowest for HR+ high-grade cancer.

Conclusions

HR+ breast cancer is increasing in incidence among premenopausal women, and HR+ high-grade cancer was associated with reduced survival among women aged 20-29 years. Our findings can help guide further evaluation of preventive, diagnostic, and therapeutic strategies for breast cancer among premenopausal women.
dc.identifier

pkz040

dc.identifier.issn

2515-5091

dc.identifier.issn

2515-5091

dc.identifier.uri

https://hdl.handle.net/10161/29970

dc.language

eng

dc.publisher

Oxford University Press (OUP)

dc.relation.ispartof

JNCI cancer spectrum

dc.relation.isversionof

10.1093/jncics/pkz040

dc.rights.uri

https://creativecommons.org/licenses/by-nc/4.0

dc.title

Incidence and Survival Among Young Women With Stage I-III Breast Cancer: SEER 2000-2015.

dc.type

Journal article

duke.contributor.orcid

Thomas, Alexandra|0000-0001-9022-2229

pubs.begin-page

pkz040

pubs.issue

3

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Medicine

pubs.organisational-group

Medicine, Medical Oncology

pubs.publication-status

Published

pubs.volume

3

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Incidence and Survival Among Young Women With Stage I-III Breast Cancer SEER 2000-2015.pdf
Size:
1.09 MB
Format:
Adobe Portable Document Format